NCT05668741: An ongoing trial by Vertex Pharmaceuticals Incorporated
This trial is ongoing. It must report results 2 years from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05668741 |
|---|---|
| Title | A Phase 1/2 Dose Escalation Study Evaluating the Safety, and Tolerability and Efficacy of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 27, 2023 |
| Completion date | Dec. 23, 2026 |
| Required reporting date | Dec. 23, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |